Besides, pyrotinib has demonstrated a good potential to treat advanced NSCLC with ERBB2 mutations, especially the ERBB2 exon 20 insertions, in the phase II studies (40, 41). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.